MedTrace Logo

Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia

NCT00511628 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1717

Last updated 2011-05-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of risperidone treatment in patients who are overweight and/or obese.

Conditions

  • Schizophrenia
  • Schizoaffective Disorder
  • Schizophreniform Disorder

Interventions

DRUG

Risperidone

As prescribed

Sponsors & Collaborators

  • Janssen-Cilag, S.A.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag S.A. (formerly Janssen Sp) Clinical Trial · Janssen-Cilag, S.A.

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-07-31
Completion
2003-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00511628 on ClinicalTrials.gov